During animal development, cells divide and arrange themselves in a coordinated way, eventually forming the embryo. The cells communicate with one another during this process through cell-surface ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

Porton Advanced Solutions and EVA Pharma have signed an MoU to enhance the development capabilities for CAR T-cell therapies.

In healthy adults, a single low dose of IMP761 continues to be safe and appears to reduce the activity of T-cells, a clinical ...

Cancer: «forgotten» cells go on the offensive. UNIGE Immunologists have discovered the yet unsuspected anti-tumour potential ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced the appointment of Christoph Broja, a ...

Recurrence means that cancer has come back after initial treatment and a period during which it could not be detected. Even ...

It has been known for several years that abnormal chromosome numbers lead to protein imbalances in the affected cells.

The company’s mocravimod, a novel oral S1P receptor, is being evaluated for its efficacy as an addition to CAR-T cell ...